TY - JOUR
T1 - 18F-FEAC and 18F-FEDAC
T2 - PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain
AU - Yui, Joji
AU - Maeda, Jun
AU - Kumata, Katsushi
AU - Kawamura, Kazunori
AU - Yanamoto, Kazuhiko
AU - Hatori, Akiko
AU - Yamasaki, Tomoteru
AU - Nengaki, Nobuki
AU - Higuchi, Makoto
AU - Zhang, Ming Rong
PY - 2010/8
Y1 - 2010/8
N2 - We evaluated two 18F-labeled PET ligands, N-benzyl-N-ethyl-2-[7, 8-dihydro-7-(2-18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl] acetamide (18F-FEAC) and N-benzyl-N-methyl-2-[7,8-dihydro-7-(2- 18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide ( 18F-FEDAC), by investigating their kinetics in the monkey brain and by performing in vitro and in vivo imaging of translocator protein (18 kDa) (TSPO) in the infarcted rat brain. Methods: Dissection was used to determine the distribution of 18F-FEAC and 18F-FEDAC in mice, whereas PET was used for a monkey. With each 18F-ligand, in vitro autoradiography and small-animal PET were performed on infarcted rat brains. Results: 18F-FEAC and 18F-FEDAC had a high uptake of radioactivity in the heart, lung, and other TSPO-rich organs of mice. In vitro autoradiography showed that the binding of each 18F-ligand significantly increased on the ipsilateral side of rat brains, compared with the contralateral side. In a small-animal PET study, PET summation images showed the contrast of radioactivity between ipsilateral and contralateral sides. Pretreatment with TSPO ligands N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8- dihydro-9H-purin-9-yl) acetamide (AC-5216) or (R)-N-methyl-N-(1-methylpropyl)-1- (2-chlorophenyl)isoquinoline-3-carboxamide (PK11195) diminished the difference in uptake between the 2 sides. The PET study showed that each 18F-ligand had uptake and distribution patterns in the monkey brain similar to those of 11C-AC-5216. After injection into the monkey during PET, the uptake of each 18F-ligand in the brain decreased over time whereas 11C-AC-5216 did not. In the brain homogenate of mice, the percentage of the fraction corresponding to intact 18F-FEAC and 18F-FEDAC was 68% and 75% at 30 min after injection. In monkey plasma, each 18F-ligand was scarcely metabolized until the end of the PET scan. Conclusion: 18F-FEAC and 18F-FEDAC produced in vitro and in vivo signals allowing visualization of the increase in TSPO expression in the infarcted rat brain. The kinetics of both 18F- ligands in the monkey brain and tolerance for in vivo metabolism suggested their usefulness. for imaging studies of TSPO in primates.
AB - We evaluated two 18F-labeled PET ligands, N-benzyl-N-ethyl-2-[7, 8-dihydro-7-(2-18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl] acetamide (18F-FEAC) and N-benzyl-N-methyl-2-[7,8-dihydro-7-(2- 18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide ( 18F-FEDAC), by investigating their kinetics in the monkey brain and by performing in vitro and in vivo imaging of translocator protein (18 kDa) (TSPO) in the infarcted rat brain. Methods: Dissection was used to determine the distribution of 18F-FEAC and 18F-FEDAC in mice, whereas PET was used for a monkey. With each 18F-ligand, in vitro autoradiography and small-animal PET were performed on infarcted rat brains. Results: 18F-FEAC and 18F-FEDAC had a high uptake of radioactivity in the heart, lung, and other TSPO-rich organs of mice. In vitro autoradiography showed that the binding of each 18F-ligand significantly increased on the ipsilateral side of rat brains, compared with the contralateral side. In a small-animal PET study, PET summation images showed the contrast of radioactivity between ipsilateral and contralateral sides. Pretreatment with TSPO ligands N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8- dihydro-9H-purin-9-yl) acetamide (AC-5216) or (R)-N-methyl-N-(1-methylpropyl)-1- (2-chlorophenyl)isoquinoline-3-carboxamide (PK11195) diminished the difference in uptake between the 2 sides. The PET study showed that each 18F-ligand had uptake and distribution patterns in the monkey brain similar to those of 11C-AC-5216. After injection into the monkey during PET, the uptake of each 18F-ligand in the brain decreased over time whereas 11C-AC-5216 did not. In the brain homogenate of mice, the percentage of the fraction corresponding to intact 18F-FEAC and 18F-FEDAC was 68% and 75% at 30 min after injection. In monkey plasma, each 18F-ligand was scarcely metabolized until the end of the PET scan. Conclusion: 18F-FEAC and 18F-FEDAC produced in vitro and in vivo signals allowing visualization of the increase in TSPO expression in the infarcted rat brain. The kinetics of both 18F- ligands in the monkey brain and tolerance for in vivo metabolism suggested their usefulness. for imaging studies of TSPO in primates.
UR - http://www.scopus.com/inward/record.url?scp=77956208191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956208191&partnerID=8YFLogxK
U2 - 10.2967/jnumed.109.072223
DO - 10.2967/jnumed.109.072223
M3 - Article
C2 - 20660373
AN - SCOPUS:77956208191
SN - 0161-5505
VL - 51
SP - 1301
EP - 1309
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 8
ER -